Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine
The study indicated enhanced delivery of colchicine using the company’s proprietary DehydraTECH(TM) technology Lexaria collaborates with the National Research Council (“NRC”), Canada’s leading research and technology organization The company has 20 patents granted and over 50 pending patents in over 40 countries around the world The global market for advanced drug delivery systems was valued at $231 billion in 2020 and is expected to grow to $310 billion by 2025 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the tolerability and pharmacokinetic study entitled VIRAL-A20-3 was completed and yielded positive results. The study demonstrated…